Experimental cancer drug begins human testing in patients out of options
NCT ID NCT06636435
Summary
This is the first human study of an experimental antibody drug called CBA-1205 for people with advanced solid tumors that haven't responded to standard treatments. The trial will test the drug's safety and find the right dose in 66 adults and children with various cancers including liver cancer and melanoma. Researchers will monitor how patients tolerate the drug and whether it shows any signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kanagawa Cancer Center
RECRUITINGYokohama, Kanagawa, 241-8515, Japan
-
National Cancer Center Hospital
RECRUITINGChūō, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, 277-8577, Japan
-
Niigata University Medical and Dental Hospital
RECRUITINGNiigata, Niigata, 951-8520, Japan
-
University of Yamanashi Hospital
RECRUITINGChūō, Yamanashi, 409-3898, Japan
Conditions
Explore the condition pages connected to this study.